This upregulation occurs concurrently with a downregulation of INK4A and ARF in prostate cancer, NSCLC, and colon cancers [16,17,18], supporting the notion that repression of the INK4A/ARF locus contributes to BMI1-stimulated tumorigenesis. Here, CDKN2A is linked to prostate cancer.